Dr. Reddy’s to field Allegra-D store-brand equivalent
HYDERABAD, India — Dr. Reddy’s Labs on Tuesday announced that it has launched its over-the-counter fexofenadine and pseudoephedrine extended-release tablets.
Dr. Reddy’s will market the product, the equivalent to Allegra-D 24 Hour, under store-brand labels in the U.S. market, the company stated.
Quarterly sales of Allegra-D totaled $13.5 million for the 12 weeks ended Aug. 7, according to SymphonyIRI Group tabulating sales across food, drug and mass (minus Walmart) outlets.
Eisai drug shows ‘significant’ reduction in epileptic seizures
WOODCLIFF LAKE, N.J. — A drug under late-stage clinical development by Eisai reduced the frequency of seizures in patients with epilepsy, according to trial results the drug maker presented Tuesday at the 2011 International Epilepsy Congress.
In a 389-patient phase-3 study of the drug perampanel, patients with partial-onset seizures who took the drug in 8-mg and 12-mg doses showed statistically significant reductions in median seizure frequency compared with those who took the placebo while receiving treatment with one to three other epilepsy drugs. The study, dubbed "Study 305," was the third in a phase-3 trial program that enrolled a total of 1,480 patients worldwide.
In the study, 14.7% of patients taking the placebo showed a reduction in seizure frequency by 50% or more, compared with 33.3% of patients taking perampanel in the 8-mg strength and 33.9% of those taking the 12-mg strength. Also, while patients in the placebo group showed a reduction in median seizure frequency of 9.7%, those taking perampanel in the 8-mg strength once per day showed a reduction of 30.5%, while those taking it the 12-mg strength once daily showed a 17.6% reduction.
"This third phase-3 study demonstrated the statistical significance and clinical efficacy of perampanel for reducing partial-onset seizures among epilepsy patients," Eisai Neuroscience Product Creation Unit president Lynn Kramer said. "Eisai is committed to developing new therapies that can offer seizure control and address unmet medical needs, as part of our [human healthcare] corporate mission."
Diabetes Prevention and Control Alliance’s Not Me program makes way to Houston
HOUSTON — The Diabetes Prevention and Control Alliance has kicked off its national campaign designed to combat the growing epidemic of Type 2 diabetes.
Not Me — an employer- and community-based initiative launched by the DPCA, a coalition launched last year by the UnitedHealth Group and several other organizations — kicked off in Houston with an event at the Tellepsen Family Downtown YMCA for healthcare employer groups and healthcare providers, hosted by the Houston Wellness Association.
The event featured Ann Albright, director of the division of diabetes translation for the Centers for Disease Control and Prevention, as the keynote speaker.
"To help us change the course of diabetes in America, we need health professionals, lay workers, employers and the private sector," Albright said. "Our goal at the CDC is by 2020 for 15 million Americans to improve their long-term health through the National Diabetes Prevention Program. The Y has projected that it can reach about 6 million of these people. So, clearly, we need even more partners to come on board."
Not Me is anchored by the the diabetes prevention program, a 16-session lifestyle intervention that is part of the CDC-led National Diabetes Prevention program, and the diabetes control program, connects people with diabetes with patient care pharmacists for private, one-on-one consultations that provide education and support to help people with diabetes better control their condition, as well as reduce the risk of developing complications from diabetes.
Houston is 1-of-6 cities that are participating in the Not Me program. Houston’s Not Me program is supported by UnitedHealthcare, the YMCA of Greater Houston and supermarket retailer Kroger.
"Diabetes is taking a devastating toll on the children, families and communities of Houston, but we have a program that is proven to help prevent the disease," said David Milich, CEO of UnitedHealthcare employer and individual of South Texas. "The good news is that Type 2 diabetes is largely preventable. It is the small lifestyle decisions we make every day that make the biggest impact. The introduction of DPCA programs provides an opportunity for Houston residents to take control of their own health and tackle this disease."